Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Get Free Report)’s stock price rose 6.3% during trading on Monday. The stock traded as high as $9.79 and last traded at $9.65. 343,567 shares were traded during trading, a decline of 72% from the average session volume of 1,225,672 shares. The stock had previously closed at $9.08.
Analyst Ratings Changes
A number of research firms recently weighed in on ZVRA. BTIG Research lowered their target price on shares of Zevra Therapeutics from $24.00 to $21.00 and set a “buy” rating on the stock in a report on Friday. Weiss Ratings reiterated a “hold (c)” rating on shares of Zevra Therapeutics in a research note on Wednesday, August 19th. Guggenheim cut their price target on Zevra Therapeutics from $23.00 to $18.00 and set a “buy” rating for the company in a research note on Monday. Citizens Jmp boosted their price objective on Zevra Therapeutics from $25.00 to $28.00 and gave the stock a “market outperform” rating in a report on Thursday, August 6th. Finally, William Blair raised Zevra Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 23rd. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $23.86.
Read Our Latest Report on ZVRA
Zevra Therapeutics Price Performance
The company’s fifty day moving average price is $10.99 and its 200 day moving average price is $10.83. The company has a market cap of $558.16 million, a PE ratio of 7.87 and a beta of 1.01.
Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) last released its quarterly earnings results on Tuesday, November 3rd. The company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.16 by $0.10. Zevra Therapeutics had a net margin of 52.80% and a return on equity of 54.64%. The business had revenue of $37.76 million for the quarter, compared to analysts’ expectations of $37.08 million. On average, analysts forecast that Zevra Therapeutics, Inc. will post 0.88 EPS for the current year.
Insider Activity at Zevra Therapeutics
In other Zevra Therapeutics news, CEO Neil McFarlane sold 20,000 shares of Zevra Therapeutics stock in a transaction that occurred on Monday, October 12th. The shares were sold at an average price of $11.25, for a total transaction of $225,000.00. Following the transaction, the chief executive officer owned 417,225 shares of the company’s stock, valued at $4,693,781.25. This trade represents a 4.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.70% of the stock is currently owned by corporate insiders.
Institutional Trading of Zevra Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of the business. Integrated Wealth Concepts LLC bought a new stake in Zevra Therapeutics during the second quarter worth $28,000. Fulcrum Asset Management LLP purchased a new position in Zevra Therapeutics in the third quarter worth $31,000. Mirae Asset Global Investments Co. Ltd. bought a new position in Zevra Therapeutics in the 3rd quarter valued at $33,000. State of Alaska Department of Revenue bought a new position in Zevra Therapeutics in the 3rd quarter valued at $44,000. Finally, State of Wyoming purchased a new stake in shares of Zevra Therapeutics during the 3rd quarter valued at $81,000. 35.03% of the stock is owned by hedge funds and other institutional investors.
Zevra Therapeutics Company Profile
Zevra Therapeutics, Inc. is a U.S.-based biopharmaceutical company focused on developing and commercializing treatments for rare diseases. Its work includes research and development as well as bringing therapies to patients with limited treatment options. The company’s products include MIPLYFFA (arimoclomol), approved in the United States for neurological manifestations of Niemann-Pick disease type C, and OLPRUVA (sodium phenylbutyrate), a treatment for certain urea cycle disorders. Zevra also advances investigational therapies for rare and complex conditions.
Featured Stories
- Five stocks we like better than Zevra Therapeutics
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
- Embraer’s Record Backlog Looks Promising, But Can It Keep Its Margins Climbing?
Receive News & Ratings for Zevra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zevra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
